| Code | CSB-RA006044MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Axatilimab-csfr, targeting the colony-stimulating factor 1 receptor (CSF1R), a cell surface tyrosine kinase receptor critical for the survival, proliferation, and differentiation of mononuclear phagocytes, including macrophages and monocytes. CSF1R signaling plays a pivotal role in regulating innate immunity and tissue homeostasis. Dysregulated CSF1R activity is implicated in various pathological conditions, including chronic graft-versus-host disease (cGVHD), tumor-associated macrophage infiltration in cancer, and inflammatory disorders where macrophage-mediated tissue damage occurs.
Axatilimab-csfr is a therapeutic antibody that functions by blocking CSF1R signaling, thereby modulating macrophage and monocyte function. This biosimilar provides researchers with a valuable tool for investigating CSF1R-mediated pathways in immunology, oncology, and inflammatory disease models. It enables studies exploring macrophage depletion strategies, immune microenvironment modulation, and the therapeutic potential of CSF1R inhibition across various disease contexts. The antibody is suitable for advancing preclinical research in immune regulation and targeted therapy development.
There are currently no reviews for this product.